Lantern Net Invested Capital vs Cash And Short Term Investments Analysis

LTRN Stock

USD 3.08 0.13 4.41%

Lantern Pharma financial indicator trend analysis is infinitely more than just investigating Lantern Pharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lantern Pharma is a good investment. Please check the relationship between Lantern Pharma Net Invested Capital and its Cash And Short Term Investments accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.

Net Invested Capital vs Cash And Short Term Investments

Net Invested Capital vs Cash And Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lantern Pharma Net Invested Capital account and Cash And Short Term Investments. At this time, the significance of the direction appears to have totally related.

The correlation between Lantern Pharma's Net Invested Capital and Cash And Short Term Investments is 1.0. Overlapping area represents the amount of variation of Net Invested Capital that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Lantern Pharma, assuming nothing else is changed. The correlation between historical values of Lantern Pharma's Net Invested Capital and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Invested Capital of Lantern Pharma are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Net Invested Capital i.e., Lantern Pharma's Net Invested Capital and Cash And Short Term Investments go up and down completely randomly.

Correlation Coefficient

1.0

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Net Invested Capital

The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Lantern Pharma balance sheet. This account contains Lantern Pharma investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Lantern Pharma fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Most indicators from Lantern Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lantern Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.As of the 23rd of November 2024, Selling General Administrative is likely to drop to about 4.2 M. Issuance Of Capital Stock is expected to grow at the current pace this year

Lantern Pharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Capital Surpluse	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Property Plant Equipment	Other Assets	Other Current Assets
Total Assets		0.76	0.92	1.0	0.98	0.79	-0.99	-0.79	0.62	0.99	0.8	0.03	1.0	-0.89	0.95	0.92	0.97	0.93	1.0	1.0	-0.88	1.0	-0.89	0.86	0.39	0.83
Other Current Liab	0.76		0.94	0.75	0.85	0.81	-0.65	-0.86	0.75	0.65	0.46	-0.19	0.76	-0.63	0.91	0.84	0.86	0.94	0.75	0.76	-0.64	0.75	-0.63	0.53	0.03	0.78
Total Current Liabilities	0.92	0.94		0.92	0.95	0.82	-0.85	-0.88	0.72	0.85	0.59	-0.11	0.92	-0.8	0.99	0.92	0.97	1.0	0.92	0.92	-0.8	0.92	-0.8	0.68	0.14	0.9
Total Stockholder Equity	1.0	0.75	0.92		0.98	0.79	-0.99	-0.78	0.61	0.99	0.8	0.03	1.0	-0.89	0.95	0.91	0.97	0.92	1.0	1.0	-0.88	1.0	-0.89	0.87	0.39	0.82
Net Tangible Assets	0.98	0.85	0.95	0.98		0.84	-0.94	-0.84	0.69	0.94	0.76	0.02	0.98	-0.89	0.97	0.93	0.99	0.96	0.98	0.98	-0.88	0.98	-0.89	0.81	0.31	0.83
Property Plant And Equipment Net	0.79	0.81	0.82	0.79	0.84		-0.73	-0.93	0.93	0.74	0.67	0.03	0.79	-0.8	0.87	0.94	0.85	0.83	0.79	0.79	-0.78	0.79	-0.8	0.69	0.14	0.67
Net Debt	-0.99	-0.65	-0.85	-0.99	-0.94	-0.73		0.71	-0.53	-1.0	-0.82	-0.07	-0.99	0.89	-0.89	-0.86	-0.93	-0.86	-0.99	-0.99	0.87	-0.99	0.89	-0.88	-0.45	-0.77
Retained Earnings	-0.79	-0.86	-0.88	-0.78	-0.84	-0.93	0.71		-0.96	-0.72	-0.45	-0.08	-0.78	0.85	-0.89	-0.96	-0.88	-0.89	-0.78	-0.79	0.83	-0.78	0.84	-0.51	0.15	-0.86
Accounts Payable	0.62	0.75	0.72	0.61	0.69	0.93	-0.53	-0.96		0.54	0.38	0.17	0.61	-0.74	0.75	0.88	0.73	0.73	0.61	0.62	-0.71	0.61	-0.74	0.39	-0.23	0.68
Cash	0.99	0.65	0.85	0.99	0.94	0.74	-1.0	-0.72	0.54		0.82	0.07	0.99	-0.89	0.9	0.87	0.93	0.86	0.99	0.99	-0.88	0.99	-0.89	0.88	0.45	0.78
Non Current Assets Total	0.8	0.46	0.59	0.8	0.76	0.67	-0.82	-0.45	0.38	0.82		0.13	0.8	-0.61	0.69	0.65	0.7	0.6	0.8	0.79	-0.57	0.8	-0.61	0.98	0.79	0.33
Non Currrent Assets Other	0.03	-0.19	-0.11	0.03	0.02	0.03	-0.07	-0.08	0.17	0.07	0.13		0.03	-0.18	-0.04	0.06	0.04	-0.09	0.03	0.03	-0.01	0.03	-0.19	0.0	-0.1	0.03
Cash And Short Term Investments	1.0	0.76	0.92	1.0	0.98	0.79	-0.99	-0.78	0.61	0.99	0.8	0.03		-0.89	0.95	0.91	0.97	0.93	1.0	1.0	-0.88	1.0	-0.89	0.87	0.39	0.82
Common Stock Total Equity	-0.89	-0.63	-0.8	-0.89	-0.89	-0.8	0.89	0.85	-0.74	-0.89	-0.61	-0.18	-0.89		-0.83	-0.91	-0.91	-0.82	-0.89	-0.89	0.98	-0.89	1.0	-0.66	-0.08	-0.83
Common Stock Shares Outstanding	0.95	0.91	0.99	0.95	0.97	0.87	-0.89	-0.89	0.75	0.9	0.69	-0.04	0.95	-0.83		0.95	0.98	0.99	0.95	0.95	-0.82	0.95	-0.83	0.76	0.23	0.87
Capital Surpluse	0.92	0.84	0.92	0.91	0.93	0.94	-0.86	-0.96	0.88	0.87	0.65	0.06	0.91	-0.91	0.95		0.96	0.93	0.91	0.92	-0.9	0.91	-0.91	0.7	0.09	0.86
Other Stockholder Equity	0.97	0.86	0.97	0.97	0.99	0.85	-0.93	-0.88	0.73	0.93	0.7	0.04	0.97	-0.91	0.98	0.96		0.98	0.97	0.97	-0.89	0.97	-0.91	0.76	0.22	0.89
Total Liab	0.93	0.94	1.0	0.92	0.96	0.83	-0.86	-0.89	0.73	0.86	0.6	-0.09	0.93	-0.82	0.99	0.93	0.98		0.92	0.93	-0.82	0.93	-0.82	0.69	0.14	0.9
Net Invested Capital	1.0	0.75	0.92	1.0	0.98	0.79	-0.99	-0.78	0.61	0.99	0.8	0.03	1.0	-0.89	0.95	0.91	0.97	0.92		1.0	-0.88	1.0	-0.89	0.87	0.39	0.82
Total Current Assets	1.0	0.76	0.92	1.0	0.98	0.79	-0.99	-0.79	0.62	0.99	0.79	0.03	1.0	-0.89	0.95	0.92	0.97	0.93	1.0		-0.88	1.0	-0.89	0.86	0.38	0.83
Capital Stock	-0.88	-0.64	-0.8	-0.88	-0.88	-0.78	0.87	0.83	-0.71	-0.88	-0.57	-0.01	-0.88	0.98	-0.82	-0.9	-0.89	-0.82	-0.88	-0.88		-0.88	0.98	-0.65	-0.09	-0.82
Net Working Capital	1.0	0.75	0.92	1.0	0.98	0.79	-0.99	-0.78	0.61	0.99	0.8	0.03	1.0	-0.89	0.95	0.91	0.97	0.93	1.0	1.0	-0.88		-0.89	0.86	0.39	0.82
Common Stock	-0.89	-0.63	-0.8	-0.89	-0.89	-0.8	0.89	0.84	-0.74	-0.89	-0.61	-0.19	-0.89	1.0	-0.83	-0.91	-0.91	-0.82	-0.89	-0.89	0.98	-0.89		-0.66	-0.09	-0.83
Property Plant Equipment	0.86	0.53	0.68	0.87	0.81	0.69	-0.88	-0.51	0.39	0.88	0.98	0.0	0.87	-0.66	0.76	0.7	0.76	0.69	0.87	0.86	-0.65	0.86	-0.66		0.77	0.43
Other Assets	0.39	0.03	0.14	0.39	0.31	0.14	-0.45	0.15	-0.23	0.45	0.79	-0.1	0.39	-0.08	0.23	0.09	0.22	0.14	0.39	0.38	-0.09	0.39	-0.09	0.77		-0.17
Other Current Assets	0.83	0.78	0.9	0.82	0.83	0.67	-0.77	-0.86	0.68	0.78	0.33	0.03	0.82	-0.83	0.87	0.86	0.89	0.9	0.82	0.83	-0.82	0.82	-0.83	0.43	-0.17

Click cells to compare fundamentals

Lantern Pharma Account Relationship Matchups

Lantern Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.4M	20.4M	74.0M	58.8M	43.6M	36.4M
Other Current Liab	489.3K	120K	1.5M	1.8M	2.5M	1.3M
Total Current Liabilities	489.3K	552.3K	2.3M	2.8M	2.7M	1.7M
Total Stockholder Equity	943.3K	19.7M	71.6M	56.0M	40.9M	34.6M
Net Tangible Assets	943.0K	19.7M	71.6M	56.0M	64.4M	32.6M
Property Plant And Equipment Net	8.8K	21.5K	216.2K	95.7K	280.4K	294.4K
Net Debt	(1.2M)	(19.1M)	(51.3M)	(37.1M)	(21.7M)	(22.8M)
Retained Earnings	(6.8M)	(12.7M)	(25.0M)	(39.3M)	(55.2M)	(52.5M)
Accounts Payable	489.3K	432.3K	681.1K	932.4K	2.5M	2.6M
Cash	1.2M	19.2M	51.5M	37.2M	21.9M	24.1M
Non Current Assets Total	199.8K	122.7K	1.2M	113.6K	306.3K	363.2K
Cash And Short Term Investments	1.2M	19.2M	70.7M	55.2M	41.3M	34.5M
Common Stock Shares Outstanding	6.3M	6.2M	10.9M	10.9M	10.8M	9.4M
Liabilities And Stockholders Equity	1.4M	20.4M	74.0M	58.8M	43.6M	36.4M
Other Stockholder Equity	7.7M	32.4M	96.7M	95.7M	96.3M	61.0M
Total Liab	489.3K	660.8K	2.4M	2.8M	2.7M	1.8M
Net Invested Capital	929.3K	19.8M	71.6M	56.0M	40.9M	34.7M
Total Current Assets	1.2M	20.2M	72.7M	58.7M	43.3M	36.1M
Capital Stock	25.4K	622.0	1.1K	1.1K	1.1K	1.0K
Net Working Capital	743.5K	19.7M	70.4M	55.9M	40.7M	34.3M
Property Plant Equipment	8.8K	21.5K	216.2K	48.0K	55.2K	65.8K

Pair Trading with Lantern Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lantern Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lantern Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Lantern Stock

0.69	ME	23Andme Holding	Pair Corr
0.68	VALN	Valneva SE ADR	Pair Corr

Moving against Lantern Stock

0.49	KZR	Kezar Life Sciences	Pair Corr
0.41	MLYS	Mineralys Therapeutics,	Pair Corr
0.4	NXGLW	NexGel Warrant	Pair Corr

The ability to find closely correlated positions to Lantern Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lantern Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lantern Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lantern Pharma to buy it.

The correlation of Lantern Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lantern Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lantern Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Lantern Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Lantern Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lantern Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lantern Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lantern Pharma Stock:

How To Invest In Lantern

Details

Is Lantern Stock a good investment?

Details

What is Lantern Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.

You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.78)

Return On Assets

(0.28)

Return On Equity

(0.45)

The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lantern Net Invested Capital vs Cash And Short Term Investments Analysis

Net Invested Capital vs Cash And Short Term Investments

Net Invested Capital vs Cash And Short Term Investments Correlation Analysis

Correlation Coefficient

Net Invested Capital

Cash And Short Term Investments

Lantern Pharma fundamental ratios Correlations

Lantern Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lantern Pharma fundamental ratios Accounts

Pair Trading with Lantern Pharma

Moving together with Lantern Stock

Moving against Lantern Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities

Cash	- 1.0	Net Debt
Net Working Capital	- 0.99	Net Debt
Total Current Assets	- 0.99	Net Debt
Net Invested Capital	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Net Debt	- 0.99	Total Stockholder Equity